-
Two new drugs for treatment of hepatitis C; NSAIDs and myocardial infarction risk; AIM-HIGH clinical trial stopped; and FDA actions.
-
The authors conclude that even short-term treatment with most NSAIDs was associated with increased risk of death and recurrent MI in patients with prior MI. Neither short- nor long-term treatment with NSAIDs is advised in this population, and any NSAID use should be limited from a cardiovascular safety point of view.
-
The Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) study showed that in patients with stable coronary artery disease (CAD) put on optimal medical therapy (OMT) that randomization to a percutaneous coronary intervention did not improve survival or prevent myocardial infarction.
-
-
It is believed that returning blood flow to chronically ischemic but viable myocardium in patients with heart failure due to coronary artery disease will improve symptoms and reduce mortality.
-
Hypertension is usually asymptomatic, so adherence to drug therapy is an issue, especially if the drugs used cause symptoms.
-
The province of Ontario in Canada maintains a comprehensive database of all implantable cardioverter-defibrillator (ICD) implants.
-
-
Patients with significant coronary artery disease (CAD) and left ventricular (LV) dysfunction are at high risk for death and hospitalization.
-
Cerebrovascular events (CVE), including stroke and transient ischemic attack (TIA), are recognized complications of percutaneous coronary intervention (PCI).
